Tumor-promoting Immune-suppressive Myeloid-derived Suppressor Cells in the Multiple Myeloma Microenvironment in Humans

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Jan 17

PMID 23321256

Citations 232

Authors

Gullu Topal Gorgun

Gregory Whitehill

Jennifer L Anderson

Teru Hideshima

Craig Maguire

Jacob Laubach

Noopur Raje

Nikhil C Munshi

Paul G Richardson

Kenneth C Anderson

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been characterized in infections, inflammatory diseases, and solid tumors; however, their presence and role in the tumor-promoting, immune-suppressive microenvironment in hematologic malignancies remains unclear. We assessed the presence, frequency, and functional characteristics of MDSCs in patients with newly diagnosed, relapsed, and relapsed/refractory multiple myeloma (MM) compared with healthy donors. Additionally, we evaluated the immunomodulatory effects of lenalidomide and bortezomib on MDSCs in MM. CD11b(+)CD14(-)HLA-DR(-/low)CD33(+)CD15(+) MDSCs were significantly increased in both the peripheral blood and the bone marrow of patients with active MM compared with healthy donors. Furthermore, MDSCs induced MM growth while suppressing T-cell-mediated immune responses. Conversely, MM cells induced the development of MDSCs from healthy donor peripheral blood mononuclear cells, confirming a bidirectional interaction between MDSCs and MM cells and immune effector cells. Our results further suggest that MDSCs may be associated with the activity of disease in MM. Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy.

Citing Articles

A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients.

Wang M, Yue X, Ding Y, Cai Z, Xiao H, Huang H J Inflamm Res. 2025; 18:2077-2090.

PMID: 39959644 PMC: 11829637. DOI: 10.2147/JIR.S495284.

Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors.

Xiong W, Xiao L, Duan R, Wang Q, Xian M, Zhang C J Immunother Cancer. 2025; 13(1.

PMID: 39755583 PMC: 11749690. DOI: 10.1136/jitc-2024-008979.

Osteoimmunology in bone malignancies: a symphony with evil.

Song C, Tong T, Dai B, Zhu Y, Chen E, Zhang M J Natl Cancer Cent. 2024; 4(4):354-368.

PMID: 39735445 PMC: 11674455. DOI: 10.1016/j.jncc.2024.09.001.

New horizons in our understanding of precursor multiple myeloma and early interception.

Cordas Dos Santos D, Toenges R, Bertamini L, Alberge J, Ghobrial I Nat Rev Cancer. 2024; 24(12):867-886.

PMID: 39414947 DOI: 10.1038/s41568-024-00755-x.

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy .

Collier-Bain H, Emery A, Brown F, Causer A, Oliver R, Eddy R Brain Behav Immun Health. 2024; 42:100865.

PMID: 39411424 PMC: 11472639. DOI: 10.1016/j.bbih.2024.100865.

References

Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

Obermajer N, Muthuswamy R, Odunsi K, Edwards R, Kalinski P . PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011; 71(24):7463-70. PMC: 4993027. DOI: 10.1158/0008-5472.CAN-11-2449. View

Mahindra A, Laubach J, Raje N, Munshi N, Richardson P, Anderson K . Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012; 9(3):135-43. DOI: 10.1038/nrclinonc.2012.15. View

Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, Menu E, De Baetselier P . Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia. 2012; 26(11):2424-8. DOI: 10.1038/leu.2012.113. View

Almand B, Clark J, Nikitina E, Van Beynen J, English N, Knight S . Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2000; 166(1):678-89. DOI: 10.4049/jimmunol.166.1.678. View

Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P . Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000; 96(12):3838-46. PMC: 2734459. View

Gorgun G, Anderson K . Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy. 2011; 3(10):1253-64. DOI: 10.2217/imt.11.124. View

Emens L, Silverstein S, Khleif S, Marincola F, Galon J . Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012; 10:70. PMC: 3341195. DOI: 10.1186/1479-5876-10-70. View

Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View

10.

Prabhala R, Neri P, Bae J, Tassone P, Shammas M, Allam C . Dysfunctional T regulatory cells in multiple myeloma. Blood. 2005; 107(1):301-4. PMC: 1895365. DOI: 10.1182/blood-2005-08-3101. View

11.

Mitsiades N, Mitsiades C, Richardson P, McMullan C, Poulaki V, Fanourakis G . Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003; 101(10):4055-62. DOI: 10.1182/blood-2002-11-3514. View

12.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

13.

Sica A, Schioppa T, Mantovani A, Allavena P . Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006; 42(6):717-27. DOI: 10.1016/j.ejca.2006.01.003. View

14.

Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W . Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006; 203(12):2691-702. PMC: 2118163. DOI: 10.1084/jem.20061104. View

15.

Vuk-Pavlovic S, Bulur P, Lin Y, Qin R, Szumlanski C, Zhao X . Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2009; 70(4):443-55. PMC: 2935631. DOI: 10.1002/pros.21078. View

16.

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A . Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008; 111(8):4233-44. DOI: 10.1182/blood-2007-07-099226. View

17.

Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M . Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010; 116(17):3227-37. PMC: 2995353. DOI: 10.1182/blood-2010-04-279893. View

18.

Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V . Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett. 2008; 267(2):216-25. DOI: 10.1016/j.canlet.2008.03.012. View

19.

Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside T . Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012; 381(1-2):14-22. PMC: 3385927. DOI: 10.1016/j.jim.2012.04.004. View

20.

Lesokhin A, Hohl T, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F . Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2011; 72(4):876-86. PMC: 3288305. DOI: 10.1158/0008-5472.CAN-11-1792. View